| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE OF SEGMENT INFORMATION
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| |
|
For the Three Months Ended
July 31,
|
|
|
For the Nine Months Ended
July 31,
|
|
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| Net Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,091 |
) |
|
$ |
(965 |
) |
|
$ |
(2,999 |
) |
|
$ |
(3,975 |
) |
| Cancer Vaccines |
|
|
(1,390 |
) |
|
|
(903 |
) |
|
|
(3,261 |
) |
|
|
(3,684 |
) |
| Anti-Viral Therapeutics |
|
|
(62 |
) |
|
|
(904 |
) |
|
|
(960 |
) |
|
|
(2,565 |
) |
| Other |
|
|
(5 |
) |
|
|
(3 |
) |
|
|
11 |
|
|
|
(18 |
) |
| Total |
|
$ |
(2,548 |
) |
|
$ |
(2,775 |
) |
|
$ |
(7,209 |
) |
|
$ |
(10,242 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
2,844 |
|
|
$ |
2,797 |
|
|
$ |
8,170 |
|
|
$ |
10,266 |
|
| Less non-cash share-based compensation |
|
|
(1,217 |
) |
|
|
(1,446 |
) |
|
|
(3,507 |
) |
|
|
(5,546 |
) |
Operating costs and expenses
excluding non-cash share-based
compensation |
|
$ |
1,627 |
|
|
$ |
1,351 |
|
|
$ |
4,663 |
|
|
$ |
4,720 |
|
Operating costs and expenses excluding
non-cash share-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
713 |
|
|
$ |
421 |
|
|
$ |
1,930 |
|
|
$ |
1,823 |
|
| Cancer Vaccines |
|
|
855 |
|
|
|
376 |
|
|
|
1,966 |
|
|
|
1,571 |
|
| Anti-Viral Therapeutics |
|
|
55 |
|
|
|
552 |
|
|
|
572 |
|
|
|
1,312 |
|
| Other |
|
|
4 |
|
|
|
2 |
|
|
|
195 |
|
|
|
14 |
|
| Total |
|
$ |
1,627 |
|
|
$ |
1,351 |
|
|
$ |
4,663 |
|
|
$ |
4,720 |
|
| |
|
July 31, 2023 |
|
|
October 31, 2022 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
11,640 |
|
|
$ |
16,921 |
|
| Cancer Vaccines |
|
|
13,968 |
|
|
|
9,442 |
|
| Anti-Viral Therapeutics |
|
|
898 |
|
|
|
3,811 |
|
| Other |
|
|
72 |
|
|
|
238 |
|
| Total |
|
$ |
26,578 |
|
|
$ |
30,412 |
|
|